Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Thomas Filleron"'
Autor:
Yaniss Belaroussi, Fanny Bouteiller, Carine Bellera, David Pasquier, Maurice Perol, Didier Debieuvre, Thomas Filleron, Nicolas Girard, Roland Schott, Simone Mathoulin-Pélissier, Anne-Laure Martin, Sophie Cousin
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Treatment of metastatic non-small cell lung cancer (mNSCLC) has been modified due to the development of immunotherapy. We assessed survival outcomes (overall [OS] and progression-free [rwPFS] survivals, time-to-next-treatment [TNT]) in mNSCL
Externí odkaz:
https://doaj.org/article/d9b0e457e3b6460188e6d1f1e06df03b
Autor:
Thomas Grinda, Natacha Joyon, Amélie Lusque, Sarah Lefèvre, Laurent Arnould, Frédérique Penault-Llorca, Gaëtan Macgrogan, Isabelle Treilleux, Anne Vincent-Salomon, Juliette Haudebourg, Aurélie Maran-Gonzalez, Emmanuelle Charafe-Jauffret, Coralie Courtinard, Camille Franchet, Véronique Verriele, Etienne Brain, Patrick Tas, Cécile Blanc-Fournier, Agnès Leroux, Delphine Loussouarn, Anca Berghian, Eva Brabencova, Jean Pierre Ghnassia, Jean-Yves Scoazec, Suzette Delaloge, Thomas Filleron, Magali Lacroix-Triki
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Abstract Expression of hormone receptor (HR) for estrogens (ER) and progesterone (PR) and HER2 remains the cornerstone to define the therapeutic strategy for breast cancer patients. We aimed to compare phenotypic profiles between matched primary and
Externí odkaz:
https://doaj.org/article/f5c605ed13024aff8ffd60be2690e7ab
Autor:
Caroline Imbert, Anne Montfort, Marine Fraisse, Elie Marcheteau, Julia Gilhodes, Elodie Martin, Florie Bertrand, Marlène Marcellin, Odile Burlet-Schiltz, Anne Gonzalez de Peredo, Virginie Garcia, Stéphane Carpentier, Sophie Tartare-Deckert, Pierre Brousset, Philippe Rochaix, Florent Puisset, Thomas Filleron, Nicolas Meyer, Laurence Lamant, Thierry Levade, Bruno Ségui, Nathalie Andrieu-Abadie, Céline Colacios
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
There are many patients who do not respond to immune checkpoint inhibitor (ICI) immunotherapy. Here, the authors show a significant negative correlation between sphingosine kinase-1 (SK1) expression and survival for ICI-treated melanoma patients, and
Externí odkaz:
https://doaj.org/article/38bb744217484cb7ab770593454d6238
Autor:
Florie Bertrand, Anne Montfort, Elie Marcheteau, Caroline Imbert, Julia Gilhodes, Thomas Filleron, Philippe Rochaix, Nathalie Andrieu-Abadie, Thierry Levade, Nicolas Meyer, Céline Colacios, Bruno Ségui
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
Most melanoma patients do not respond to anti-PD1 therapy. Here, the authors show that TNFα blockade synergizes with anti-PD-1 by preventing anti-PD-1-induced CD8+ T cell death and TIM-3 expression on such cells.
Externí odkaz:
https://doaj.org/article/a4452c1e969c432987f7e542b52dfbb2